Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis

Abstract

These data suggest that the acceptable safety profile of etanercept therapy is maintained for up to 8 years in this population of JRA patients. Improvements in the signs and symptoms of JRA were also maintained for up to 8 years.